Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyax has reported that for the quarter ended March 31, 2008, it has secured a net loss of $21.3 million or $0.35 per share, as compared to a net loss of $20 million or $0.44 per share for the comparable quarter in 2007.
Subscribe to our email newsletter
Total revenues for the first quarter ended March 31, 2008 remained essentially unchanged at $2.6 million versus the comparable quarter in 2007.
Stephen Galliker, executive vice president and CFO of Dyax, said: “Following the completion of our recent deals with sanofi-aventis and Cubist Pharmaceuticals, we anticipate that our net 2008 cash consumption will not exceed our 2007 amount of $38.3 million. We expect to further reduce this cash burn, through additional partnerships and collaborations.”